Le Lézard
Classified in: Health
Subject: SVY

Contrast Media/Contrast Agent Market Worth $6.0 Billion by 2024 - Exclusive Report by MarketsandMarketstm


CHICAGO, Dec. 11, 2019 /PRNewswire/ -- According to the new market research report "Contrast Media/Contrast Agent Market by Type (Iodinated, Gadolinium, Barium and Microbubble), Procedure (X-Ray/CT, MRI and Ultrasound), Application (Radiology, Interventional Radiology and Interventional Cardiology), Region - Global Forecast to 2024", published by MarketsandMarketstm,  the Contrast Media/Contrast Agents Market is expected to reach USD 6.0 billion by 2024 from an estimated USD 5.0 billion in 2019, at a CAGR of 3.8%

MarketsandMarkets_Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

The key factors driving the growth of this market are increasing approvals for contrast agents and rising volume of CT & MRI examinations globally. 

By type, the iodinated contrast media segment is expected to account for the largest share of the market in 2019

Based on type, the contrast media market is segmented into iodinated contrast media, gadolinium-based contrast media, barium-based contrast media and microbubble contrast media. In 2019, the iodinated contrast media segment is estimated to account for the largest share of the contrast media industry. The large share of this segment can be attributed due to its high usage in CT examinations coupled with the fact that it can be used in almost all body parts.

Browse in-depth TOC on "Contrast Media Market"

121 ? Tables
37 ? Figures  
161 ? Pages

By modality, the X-Ray/CT segment is expected to account for the largest share of the market in 2019

Based on modality, the Contrast Agent Market is segmented into X-Ray/CT, MRI, and ultrasound procedures. In 2019, X-Ray/CT procedures segment is expected to command the largest share of the global contrast media market. The large share of this segment can be attributed to the increasing number of CT examinations across the globe, coupled with advancements in CT imaging technologies.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=911

North America to dominate the market in 2019

North America, Europe, Asia Pacific, and the Rest of the World (RoW) are the regions considered for geographic analysis of the global contrast media market study. North America is expected to account for the largest share of the global contrast media industry. The large share of North America is attributed to the increasing number of diagnostic imaging units and examinations, growing aging population & rising prevalence of chronic conditions in the US, significant focus & government investments in the field of medical imaging, and increasing research activities in Canada.

The prominent players in the global contrast media market include GE Healthcare (US), Bracco Imaging (Italy), Bayer (Germany), and Guerbet (France) are the major players operating in the market. Other prominent players in the market are Lantheus (US), Daiichi Sankyo (Japan), Unijules (India), J.B. Chemicals (India), Sanochemia (Austria), Taejoon Pharm (South Korea), Jodas (India), and Magnus Health (India).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Get Special Pricing on Bundle Reports:
https://www.marketsandmarkets.com/RequestBundleReport.asp?id=911

Browse Related Reports:

Diagnostic Imaging Market by Product (MRI (Open, Closed), Ultrasound (2D, 3D/4D, Doppler), CT, X-Ray (Digital, Analog), SPECT, Hybrid PET, Mammography), Application (OB/Gyn, Cardiology, Oncology), End User (Hospitals, Imaging Centers) - Forecast to 2024

Nuclear Medicine/ Radiopharmaceuticals Market
 by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023

About MarketsandMarketstm 

MarketsandMarketstm provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketstm for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarketstm are tracking global high growth markets following the "Growth Engagement Model ? GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarketstm now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarketstm is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarketstm's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/contrast-media-market.asp 
Visit Our Website: https://www.marketsandmarkets.com 
Content Source: https://www.marketsandmarkets.com/PressReleases/contrast-media.asp

SOURCE MarketsandMarkets


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: